PER Stock Overview Engages in the research and development of novel antisense pharmaceuticals in Australia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Percheron Therapeutics Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Percheron Therapeutics Historical stock prices Current Share Price AU$0.0085 52 Week High AU$0.14 52 Week Low AU$0.005 Beta 0.90 1 Month Change -88.03% 3 Month Change -91.90% 1 Year Change -85.34% 3 Year Change -95.53% 5 Year Change -90.12% Change since IPO -93.46%
Recent News & Updates Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Nov 26
Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Nov 15
New minor risk - Shareholder dilution Nov 12 Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Oct 23
Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Oct 18
Forecast to breakeven in 2027 Oct 10 See more updates Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Nov 26
Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Nov 15
New minor risk - Shareholder dilution Nov 12 Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Oct 23
Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Oct 18
Forecast to breakeven in 2027 Oct 10
High number of new and inexperienced directors Jan 30
Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023 Oct 17
New major risk - Financial position Aug 15
New minor risk - Shareholder dilution Jul 24
New minor risk - Share price stability Jul 20
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK Jun 29 Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency Feb 15
Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency Feb 13
Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD Feb 03
Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe Dec 20
Less than half of directors are independent Nov 23
Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer Nov 15
Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron Nov 14 Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022
Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer Oct 06
Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study Sep 12
Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase Sep 07
Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021) Sep 02
Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets Aug 24
Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19 Aug 19
Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe Jul 13
Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model Jun 23
Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model Jun 20
Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study Feb 08
Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential Sep 24
Forecast to breakeven in 2024 Aug 27
Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US Jun 01
Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial May 26
Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency Feb 26
Antisense Therapeutics Limited Announces Executive Changes Feb 24
New 90-day high: AU$0.20 Jan 15
Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020 Nov 17
Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control Oct 04
An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million. Sep 26
Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt Sep 07 Shareholder Returns PER AU Pharmaceuticals AU Market 7D 13.3% 3.3% -0.09% 1Y -85.3% -11.2% 8.3%
See full shareholder returns
Return vs Market: PER underperformed the Australian Market which returned 7.4% over the past year.
Price Volatility Is PER's price volatile compared to industry and market? PER volatility PER Average Weekly Movement 29.6% Pharmaceuticals Industry Average Movement 10.2% Market Average Movement 7.9% 10% most volatile stocks in AU Market 16.7% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: PER's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: PER's weekly volatility has increased from 19% to 30% over the past year.
About the Company Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
Show more Percheron Therapeutics Limited Fundamentals Summary How do Percheron Therapeutics's earnings and revenue compare to its market cap? PER fundamental statistics Market cap AU$8.48m Earnings (TTM ) -AU$11.92m Revenue (TTM ) AU$2.97m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PER income statement (TTM ) Revenue AU$2.97m Cost of Revenue AU$62.15k Gross Profit AU$2.91m Other Expenses AU$14.83m Earnings -AU$11.92m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.011 Gross Margin 97.91% Net Profit Margin -401.57% Debt/Equity Ratio 0%
How did PER perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 08:39 End of Day Share Price 2025/01/02 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Hester Bell Potter Iain Wilkie Morgans Financial Limited Dr Storey Wilsons Advisory and Stockbroking Ltd.
Show 1 more analysts 
